Research Partnerships
Clinical Trial De-Risking Through Ultra-Sensitive Monitoring

THE OPPORTUNITY

ExoDiscovery's breakthrough exosome technology transforms clinical trial efficiency, delivering substantial cost savings and improved patient outcomes through rapid, ultra-sensitive biomarker monitoring.
Discuss Opportunities
Discuss Opportunities
Potential
40% decrease
in randomized patients through
true-positive patient selection
Potential
$800K+ saved
in replacement costs by reducing
screen failure rates by 15%+
Potential
$400K+ saved
per patient through 10+ days
faster turnaround time
Potential
$160K+ saved
per patient by halting ineffective therapy
Explore partnerships
Contact Us
Contact Us
Technical Advantages
✓ Complementary integration with existing monitoring tools - enhances rather than replaces current protocols

✓ Near-zero protocol friction - seamlessly integrates into clinical workflows using standard blood collection procedures
ExoDiscovery Monitor
Speed
24-hour turnaround time
Sensitivity
10,000x greater detection capability
Efficiency
No amplification required
Sample Size
Minimal 20μL plasma
Cost
Competitive test pricing
Conventional Methods
Speed
7-14 day waiting period
Sensitivity
Limited detection threshold
Efficiency
Complex PCR/NGS processing
Sample Size
10-20mL required
Cost
Higher testing expenses
VS
1. Accuracy is calculated as the proportion of true positive and true negative results among all tested samples. Data on file. Internal case-control, blind, retrospective study with n=101. Study results may not reflect real-world outcomes. Also see: Elizabeth Maria Clarissa, Sumit Kumar, Juhee Park, Mamata Karmacharya, In-Jae Oh, Mi-Hyun Kim, Jeong-Seon Ryu, and Yoon-Kyoung Cho. Digital Profiling of Tumor Extracellular Vesicle-Associated RNAs Directly from Unprocessed Blood Plasma. ACS Nano 2025 19 (5), 5526-5538. Sensitivity is defined as the percentage of actual positives correctly identified by the test. Specificity is defined as the percentage of actual negatives correctly identified by the test. Public data suggest conventional methods in comparable screening show <40% sensitivity in early-stage disease.
Partnership Options
Core Monitoring Test Set
Ready for immediate implementation
Coverage: All stages of lung and pancreatic cancers
Target Biomarkers: EGFR, KRAS, and EML4-ALK
Timeline: 1-2 month research collaboration
Implementation Process
1. Protocol Validation - Rapid validation sample processing (4-6 weeks)
2. Sensitivity Data Discussion - Early signal detection through ultra-sensitive assay
3. Seamless Integration - Complementary monitoring tool alongside existing workflows
Customized Monitoring Test
Tailored to your
specific trial needs
Coverage: Partner-designated target cancer
Target Biomarkers: Partner-designated biomarkers
Timeline: 3-4 month research & implementation
Implementation Process
1. Biomarker Designation - Drug developer designates specific biomarkers to monitor
2. Reagent Design - ExoDiscovery designs and validates reagents (4-6 weeks)
3. Core Monitoring Process - Identical implementation as Core Monitoring
Discuss a Partnership
Even if your trial is already ongoing, ExoDiscovery can complement existing tests with faster and more actionable information.

Our platform enables:

✓ Earlier detection of treatment resistance
✓ More precise patient stratification
✓ Reduced trial timelines and costs
✓ Higher quality data for regulatory submissions
Contact us to learn more about our technology or potential partnerships.
Add context to help us understand your area of interest
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.